Lung Cancer Breakthrough: Blocking Growth Hormone Could Unlock New Treatments
Researchers at Ohio University have pinpointed a potential new weapon in the fight against lung cancer – blocking the growth hormone receptor. This discovery offers a glimmer of hope for patients battling Non-Small Cell Lung Cancer (NSCLC), particularly those whose tumors have become resistant to conventional therapies like chemotherapy, and radiation.
The Challenge of Therapy-Resistant Lung Cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide. NSCLC, accounting for 80-85% of all lung cancer cases, often develops resistance to treatment, making the disease harder to control and significantly reducing survival rates. This resistance is a major hurdle in improving patient outcomes.
How Growth Hormone Plays a Role
The research, led by Dr. John Kopchick and Arshad Ahmad at the Heritage College of Osteopathic Medicine, focuses on the role of growth hormone (GH) in NSCLC. Although GH is well-known for regulating growth and metabolism, studies suggest it can as well fuel cancer cell growth and resistance to therapy. The team’s analysis of hundreds of NSCLC patient tumor samples, utilizing data from The Cancer Genome Atlas, revealed a striking correlation: tumors with higher levels of the growth hormone receptor (GHR) were associated with significantly shorter survival times. Patients with low GHR tumors survived approximately 66 months, compared to just 36-40 months for those with high GHR tumors.
Patients with high GHR tumors survived, on average, 30 months less than those with low GHR tumors.
Laboratory Findings Confirm GH’s Impact on Chemo Resistance
Laboratory experiments using both human and mouse lung cancer cells confirmed the link between GH and treatment resistance. GH was shown to increase the activity of drug-efflux pumps – proteins that actively remove chemotherapy drugs from cancer cells, effectively neutralizing their impact. This, combined with changes promoting tumor spread and reducing cell death, made cancer cells more resilient to treatment.
Pegvisomant: A Potential Solution?
The researchers then investigated pegvisomant, a drug already approved by the U.S. Food and Drug Administration for treating acromegaly (a condition caused by excess GH). Discovered by Dr. Kopchick in 1987, pegvisomant works by blocking the growth hormone receptor. The study showed that pegvisomant reversed many of GH’s harmful effects, increasing the sensitivity of cancer cells to chemotherapy and potentially reducing the required dosage.
Pegvisomant, originally developed for acromegaly, shows promise in reversing GH’s harmful effects on cancer cells.
Future Directions: From Lab to Clinical Trials
While these findings are encouraging, the research is still in its early stages. The team plans to conduct further studies using mouse models to validate the results. Successful outcomes in these preclinical trials could pave the way for clinical trials to assess the safety and efficacy of this approach in human patients with lung cancer. Previous animal studies have shown positive results when combining pegvisomant with therapy in melanoma, pancreatic, and liver cancers.
Frequently Asked Questions
- What is NSCLC? Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for 80-85% of all cases.
- What is the growth hormone receptor? The growth hormone receptor (GHR) is a protein in cells that binds to growth hormone, influencing growth and metabolism.
- What is pegvisomant? Pegvisomant is a drug that blocks the growth hormone receptor and is currently approved for treating acromegaly.
- How does this research impact current lung cancer treatments? This research suggests that blocking the growth hormone receptor could improve the effectiveness of existing lung cancer treatments, particularly in patients with therapy-resistant tumors.
Pro Tip: Staying informed about the latest cancer research is crucial for both patients and healthcare professionals. Reliable sources like the National Cancer Institute (https://www.cancer.gov/) and the American Cancer Society (https://www.cancer.org/) offer valuable information and resources.
Want to learn more about cutting-edge cancer research? Share your thoughts in the comments below, and explore our other articles on innovative cancer therapies.
